Nabi withdraws application for Altastaph vaccine

11/2/2005 | American City Business Journals

Nabi Biopharmaceuticals said its StaphVax vaccine, for preventing staph infections among kidney disease patients, failed to meet its goals in a Phase III trial, so the company will withdraw its application for EU approval. Nabi also said it will stop developing its Altastaph, a treatment based on the StaphVax technology, but will continue developing drugs related to smoking cessation and hepatitis C.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR